AlloSure, the First dd-cfDNA in Heart and Kidney
AlloSure Significantly Improves Management of High-Risk Lung Transplant Patients...
Stay updated with breaking news from Greg Seeto. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AlloSure Significantly Improves Management of High-Risk Lung Transplant Patients...
Published: Jun 04, 2021 Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its participation in the 2021 American Transplant Congress (ATC), including two symposia and the presen...
GuruFocus Article or News written by Marketwired and the topic is about:
CDNA earnings call for the period ending March 31, 2021.
Published: Apr 23, 2021 SOUTH SAN FRANCISCO, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc., Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced experts will present its latest heart research, which was accepted at the International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, set to take place between April 24-28, 2021. CareDx’s offerings are showcased...